Peptide-based therapeutics have received increasing attention in medical research. However, the local delivery of such therapeutics poses unique challenges. Self-assembling peptides that use decorated nanofibers are one approach by which these therapeutics may be delivered. We previously found that the self-assembling K5 peptide affects the anti-inflammatory response. The aim of the present study was to investigate another self-assembling peptide, S5. Unlike the K5 peptide which has a positive charge, the S5 peptide has a free hydroxyl (-OH) group. We first examined whether the S5 peptide regulates the inflammatory response in primary cells and found that the S5 peptide reduced the production of prostaglandin E 2 (PGE 2 ) and tumor necrosis factor (TNF)-in lipopolysaccharide-(LPS-) treated bone marrow-derived macrophages. Moreover, the S5 peptide significantly downregulated cyclooxygenase-(COX-) 2, TNF-, and interleukin-(IL-) 1 expression by blocking the nuclear translocation of c-Jun. Consistent with this finding, the S5 peptide diminished the activation of inflammatory signaling enzymes related to p38. The S5 peptide also inhibited the formation of the p38/c-Jun signaling complex in RAW264.7 cells. Similarly, p38 and MKK3/6 were inhibited by the S5 peptide in LPS-activated peritoneal macrophages. Taken together, these results strongly suggest that the S5 peptide could exert anti-inflammatory effects by inhibiting the c-Jun/p38 signaling pathway.
Introduction
Innate immune responses provide four anatomical, physiological, phagocytic, and inflammatory barriers. Among these barriers, the macrophage-mediated inflammatory barrier is the most important [1] . Macrophages produce proinflammatory cytokines and other signaling molecules such as interleukins (ILs), tumor necrosis factor (TNF)-, and prostaglandins (PGs), all of which are essential for the initial inflammatory response [2] . Thus, the initial activation of macrophages is a significant event in inflammatory processes. To activate the inflammatory response, macrophage surface receptors such as Toll-like receptors (TLRs) interact with their cognate ligands [3] . Activated macrophages consequently upregulate intracellular signaling pathways to activate the nuclear factor (NF)-B pathway and the activator protein-(AP-) 1 pathway, leading to the expression of inflammatory genes [4] [5] [6] . To cure inflammatory diseases, effective regulation of the inflammatory response is required. Therefore, targeted inhibition of intracellular inflammatoryrelated signaling pathways has been considered to be a promising therapeutic strategy for treating various immunological diseases such as cancer, septic shock, diabetes, and atherosclerosis [7] [8] [9] [10] [11] . The applications of self-assembling peptides have been widely investigated. Biological hydrogels consisting of self-assembling peptide nanofibers have been shown to have a broad range of potential applications [12] [13] [14] [15] . Self-assembling peptides consist of short peptides with 8 to 16 residues that are 2.5 to 5 nm in length, depending on conditions such as pH and ionic strength [16] . These 2 Mediators of Inflammation structural features have made self-assembling systems an attractive option for tissue culture-based and tissue-based research into the mechanisms that control various cellular processes [17] . Although recent studies have indicated that self-assembling peptides have potential applications in drug delivery as a nanomedicine platform [18] , the molecular mechanisms underlying these applications are not yet fully understood.
In our previous study, we determined the immuneregulatory functions of a self-assembling peptide, K5, RADARADARADARADA-KKKKK. In the present study, we investigated another peptide named S5, RADARADARA-DARADA-SSSSS, with 5 serine resides, which was developed to investigate polarity effects on self-assembling property, plasma protein interactions, and platelet activation [19] . While the K5 peptide exhibits lysine residue-driven net positive charge at a pH of 7.4, disadvantageous in terms of membrane permeability, S5 peptide only maintains free hydroxyl group. Considering chemical property of S5, it is hypothesized that the penetration of S5 into cytoplasmic compartment in a cell might be better than K5. In this study, we aimed to demonstrate the immunopharmacological improvement of the S5 peptide in cellular and molecular inflammatory responses.
Materials and Methods

Materials.
The S5 peptide was purchased from SynBioSci (Livermore, CA, USA). Tetrazole (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), prednisolone and indomethacin, and lipopolysaccharide (LPS, E. coli 0111:B4) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Enzyme immunoassay (EIA) kits and enzymelinked immunosorbent assay (ELISA) kits for determining the levels of PGE 2 and TNF-were purchased from Thermo Scientific (NYSE: TMO) and Amersham (Little Chalfont, Buckinghamshire, UK). Fetal bovine serum (FBS), RPMI1640 and DMEM media were purchased from Thermo Scientific (NYSE: TMO). RAW264.7 and HEK293 cells were obtained from ATCC (Rockville, MD, USA). Phospho-and total protein antibodies against c-Jun, extracellular signal-related kinase (ERK), c-Jun N-terminal kinase (JNK), p38, MAP kinase kinase 3/6 (MKK3/6), TGF-activated kinase 1 (TAK1), lamin A/C, and -actin were purchased from Cell Signaling (Beverly, MA, USA) and Santa Cruz (Santa Cruz, CA, USA).
Animals.
Male ICR mice (6 weeks old, 17 to 21 g) were purchased from DAEHAN BIOLINK (Chungbuk, Korea) and housed in plastic cages under conventional conditions. Water and food pellets (Samyang, Daejeon, Korea) were supplied ad libitum. All studies were carried out in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Sungkyunkwan University (approval ID: SKKUBBI 12-6-2). 6 cells/mL) were preincubated for 18 h, after which cells were treated with the S5 peptide (0 to 100 g/mL) or standard compounds (prednisolone and indomethacin) for 30 min and then additionally treated with LPS (1 g/mL) for 24 h. Production and the release of PGE 2 and TNF-were determined by EIA and ELISA kits, as described previously [20] .
Preparation of Bone
Cell Viability Assay. Bone marrow-derived macrophages or RAW264.7 cells (1 × 10
6 cells/mL) were treated with S5 peptide (0 to 100 g/mL) for 24 h. Cytotoxic effect of S5 peptide was evaluated by conventional MTT assay as described previously [21, 22] .
mRNA Expression Analysis by Quantitative Reverse
Transcriptase-Polymerase Chain Reaction. To evaluate inflammatory gene mRNA expression levels, RAW264.7 cells pretreated with S5 peptide (0 to 100 g/mL) for 30 min were incubated with LPS (1 g/mL) for 6 h. Total RNA from the cells was then isolated with TRIzol Reagent (Gibco BRL) according to the manufacturer's instructions and stored at −70 ∘ C until use. The levels of IL-1 , TNF-, and COX-2 mRNA expression levels were quantified by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) with SYBR Premix Ex Taq according to the manufacturer's instructions (Takara, Japan). Reactions were run in a realtime thermal cycler (Bio-Rad, USA), as reported previously [23, 24] . Results are expressed as relative ratios of gene expression normalized to the internal control GAPDH. Primers were ordered from Bioneer (Seoul, Korea) and their sequences are listed in Table 1 .
Preparation of Total Lysates and Nuclear Extracts, Immunoblotting, and
Immunoprecipitation. Preparation of total lysates and nuclear extracts from LPS-treated RAW264.7 cells pretreated with S5 peptide was used, a method previously published [25] . 
Gene
Primer sequence
TNF-
and -actin] levels was performed, according to published methods [26] . For immunoprecipitations, cell lysates were generated from RAW264.7 cells (1 × 10 7 cells/mL) that had been treated either with or without LPS (1 g/mL) for 90 min. Lysates containing equal amounts of protein (500 g) were precleared with 10 L protein A-coupled Sepharose beads (50% v/v) (Amersham, UK) for 1 h at 4 ∘ C. Precleared samples were incubated overnight at 4 ∘ C with 5 L antibody to p38. Immune complexes were captured with 10 L protein Acoupled Sepharose beads (50% v/v) by rotation for 3 h at 4 ∘ C. (Figures 1 and 2 ) are expressed as means ± standard deviations (SDs) and were calculated from one of two independent experiments. Each experiment was performed with six technical replicates. The data shown in this paper are representative of three independent experiments, each of which yielded similar results. For statistical comparisons, results were analyzed using analysis of variance/Scheffe's post hoc test and the Kruskal-Wallis/MannWhitney tests. All values < 0.05 were considered statistically significant. All statistical tests were carried out using the computer program SPSS (SPSS Inc., Chicago, IL, USA).
Statistical Analysis. Data
Results and Discussion
We previously reported that the self-assembling K5 peptide, applied as 3D scaffolds for tissue engineering or drug delivery [18, 27] , downregulates the macrophage-mediated inflammatory responses [28] . The S5 peptide is part of a family of selfassembling peptides that includes the K5 peptide. However, in contrast to the K5 peptide, the S5 peptide lacks positive charge in this backbone. Since these two peptides exhibit reasonably similar structures with only a minor difference, we hypothesized that the S5 peptide would also exert antiinflammatory effects.
Similar to the pharmacological profiles of K5 peptide [28] , the S5 peptide appears to be a promising therapeutic molecule for dampening the inflammatory response. For instance, the S5 peptide decreased the production of PGE 2 (Figure 1(a) ) and TNF- (Figure 1(b) ) in both malignant RAW264.7 cells and in BM-derived LPS-activated macrophages in a dose-dependent manner as seen in the cases of standard compounds prednisolone and indomethacin (Figure 1(c)) ; importantly, no cytotoxicity was observed in these cells (Figure 1(d) ). These data raised a possibility that S5 peptide can be a peptide drug with anti-inflammatory property as previously suggested with synthetic TIP-like peptide AP318, peptides from bovine -casein, cathelicidin, and N15P polypeptide [29] [30] [31] . Since elucidating the molecular mechanisms of these effects is important for initiation of drug discovery process, we next examined the anti-inflammatory mechanism of the S5 peptide.
To examine the effects of the S5 peptide on the inflammatory response on the transcriptional level, the mRNA levels of COX-2 (Figure 2(a) ), TNF- (Figure 2(b) ), and IL-1 (Figure 2(c) ) were measured by real-time PCR in cells that had been stimulated with LPS. These experiments showed that the S5 peptide (100 g/mL) downregulated the expression of COX-2, TNF-, and IL-1 . To investigate whether the S5 peptide regulates DNA promoter activity, a luciferase reporter assay was used that resulted in cell luminescence. The S5 peptide remarkably decreased AP-1-mediated transcriptional activation in response to PMA, MyD88, or TRIF; moreover, this effect was dose-dependent (Figures 3(a), 3(b) , and 3(c)). Activation of the inflammatory response is known to result in nuclear translocation of the AP-1 transcription factor, which results in transcription of AP-1-driven target genes.
To examine the nuclear translocation of c-Jun in the inflammatory response, we determined the levels of c-Jun in the nuclear fractions of LPS-treated RAW264.7 cells. This is because peptide K5 displayed predominant inhibitory activity on AP-1 translocation. Interestingly, these experiments showed that the S5 peptide prevented the nuclear translocation of c-Jun at 60 and 90 min (Figure 3(d) ). This result implies that the S5 peptide may regulate the AP-1 signaling pathway. To investigate the activation status of upstream signaling molecules in the AP-1 pathway, the phosphorylation of various MAPKs (ERK, p38, and JNK) was analyzed by Western blotting. The phosphorylation of p38 and JNK was decreased at 30 and 15 min, while ERK phosphorylation was not decreased by the S5 peptide (Figure 4(a) ). Interestingly, the S5 peptide only prevented phosphorylation of MKK3/6, an upstream kinase of p38 [32] , whereas the S5 peptide did not prevent the phosphorylation of the upstream molecule JNK, which is downstream of MKK4/7. Phosphorylation of TAK1, a kinase that is upstream of the MKKs [33] , was also decreased by the S5 peptide (Figure 4(b) ). To determine whether the effects of the S5 peptide were recapitulated in primary cells, peritoneal macrophages were harvested from ICR mice and the phosphorylation status of various signaling molecules was investigated by Western blotting. This experiment revealed that the S5 peptide decreased the phosphorylation of c-Jun, p38, and MKK3/6 in LPS-driven signaling (Figure 4(c) ). Moreover, the S5 peptide also dramatically blocked the interaction of phospho-p38 with c-Jun and its phosphoform, as revealed by immunoprecipitation and immunoblotting analyses (Figure 4(d) ). Based on these results, we conclude that the S5 peptide is capable of preventing AP-1 signaling events. Some of strong anti-inflammatory remedies such as medicinal plant-derived extracts including Dryopteris crassirhizoma and Archidendron clypearia and their individual components including andrographolide, ginsenosides, curcumol, and lutein are known to suppress AP-1 function in their pharmacological actions [34] [35] [36] [37] [38] , suggesting that AP-1 could play a critical role in inflammationregulatory functions. Due to their size and charge, some peptides are regarded as one of membrane nonpermeable biomaterials. In contrast, most hydrophobic small chemicals are much assessable to be penetrated into the membrane and display higher possibility to directly interact with cytosolic target enzymes. However, chemical drugs showing effective inhibition property toward important signaling enzymes are faced to have another side effect causing nonspecific toxicity. In this respect, peptide drugs are considered to be favorable in terms of drug development, due to their selectivity. Previously, we reported that peptide K5 is able to suppress TNF-production in LPS-treated RAW264.7 cells up to 48% at 100 g/mL [28] . On the other hand, chemically modified S5 peptide having free OH groups exhibited stronger activity (80% inhibition at 100 g/mL) under the same conditions (Figure 1(b) ), implying that membrane permeability of peptide S5 could be more improved than K5. Nonetheless, the fact that K5 was revealed to block the release of TNF-and PGE 2 between 50 to 100 g/mL [28] is still raising a possibility that some of peptide receptor such as PEPT1, OATP2BA, or OARP1B3 [39, 40] could contribute to the uptake of peptides K5 and S5 into cytoplasm. The point that S5 peptide exhibits higher anti-inflammatory property under improved membrane permeability seems to impose S5 peptide to be developed as anti-inflammatory peptide drug. Indeed, some peptides such as GLP and its analogs, extracellular matrix protein-derived peptides [41] , and integrin-binding N-terminal peptides [42] are closed to be developed as antitumorigenic remedy, although the therapeutic use of these peptides is still limited due to high cost, poor stability, and mediocre pharmacokinetics [18] . In cases of the S5 and K5 peptides, these are known to be selfassembling nanopeptides forming a hydrogel applied for drug delivery system and have been shown to be nonimmunogenic and noninvasive in the filling of cavities [15, 18, 43] . According to our results, these peptides are found to have antiinflammatory properties which can give additional benefits when they are used as carrier to deliver immunomodulatory drugs. Since the S5 peptide itself suppresses events in the TLR4 signaling pathway, including activation of MAPK and AP-1, it may exert a synergetic effect if carrier molecules are NF-B-targeted anti-inflammatory drugs.
To sum up these results, here we showed that the S5 peptide dampens various components of the TLR4-mediated inflammatory response, such as the production of PGE 2 and TNF-. In addition, the S5 peptide reduces AP-1 signaling by preventing the phosphorylation of MKK3/6 and TAK1, as summarized in Figure 5 . Since the S5 peptide is a selfassembling peptide that could be used for drug delivery, it is possible that the S5 peptide could be loaded with therapeutics that target AP-1 or other compounds that synergize with inflammatory molecules. Future studies will test the efficacy of the S5 peptide as a drug carrier and as an antiinflammatory agent in an animal model. These experiments have the potential to contribute to the development of an efficacious and novel drug delivery system.
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